Experimental Approach
Passively sensitized human airways were treated with benralizumab and
mepolizumab. The primary endpoint was the inhibition of AHR to
histamine; the secondary endpoints were the protective effect against
AHR to parasympathetic activation and mechanical stress, and the tissue
modulation of cAMP.